Clarenicol oral liquid for throat symptom relief in COVID-19 convalescent, suspected, and susceptible adults

Phase 4, open-label, single-arm trial of clarenicol in pharyngitis and coronavirus disease 2019 (COVID-19), sponsored by Dongguan People's Hospital. Primary endpoints: Relief time and relief rate of pharyngeal discomfort symptoms, Time required for resolution or relief of new fever, cough, muscle soreness, and headache and 1 more. Planned start Jun 2020; status: not yet recruiting.